MX368178B - Compuestos de ácido dimetilbenzoico. - Google Patents

Compuestos de ácido dimetilbenzoico.

Info

Publication number
MX368178B
MX368178B MX2016007861A MX2016007861A MX368178B MX 368178 B MX368178 B MX 368178B MX 2016007861 A MX2016007861 A MX 2016007861A MX 2016007861 A MX2016007861 A MX 2016007861A MX 368178 B MX368178 B MX 368178B
Authority
MX
Mexico
Prior art keywords
acid compounds
dimethylbenzoic acid
dimethylbenzoic
receptor
inhibitor
Prior art date
Application number
MX2016007861A
Other languages
English (en)
Other versions
MX2016007861A (es
Inventor
Blanco-Pillado Maria-Jesus
Natali Vetman Tatiana
Allen Schiffler Matthew
Schulenburg York Jeremy
Rudolph Manninen Peter
M Warshawsky Alan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016007861A publication Critical patent/MX2016007861A/es
Publication of MX368178B publication Critical patent/MX368178B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(ver Fórmula) La presente invención proporciona un compuesto de la fórmula I: en donde A es: y W, Y, X, R1, R2, R3 y R4 son como se definen en la presente, o una sal de éste aceptable desde el punto de vista farmacéutico, para uso como un inhibidor del receptor de EP4.
MX2016007861A 2013-12-17 2014-12-11 Compuestos de ácido dimetilbenzoico. MX368178B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361916824P 2013-12-17 2013-12-17
PCT/US2014/069783 WO2015094912A1 (en) 2013-12-17 2014-12-11 Dimethylbenzoic acid compounds

Publications (2)

Publication Number Publication Date
MX2016007861A MX2016007861A (es) 2017-01-11
MX368178B true MX368178B (es) 2019-09-23

Family

ID=52355186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007861A MX368178B (es) 2013-12-17 2014-12-11 Compuestos de ácido dimetilbenzoico.

Country Status (23)

Country Link
US (1) US10005721B2 (es)
EP (1) EP3083554B1 (es)
JP (1) JP6200596B2 (es)
KR (1) KR101937186B1 (es)
CN (1) CN105793236B (es)
AU (1) AU2014366371B2 (es)
CA (1) CA2929562A1 (es)
CY (1) CY1121677T1 (es)
DK (1) DK3083554T3 (es)
EA (1) EA028675B1 (es)
ES (1) ES2727329T3 (es)
HR (1) HRP20190793T1 (es)
HU (1) HUE043614T2 (es)
LT (1) LT3083554T (es)
ME (1) ME03398B (es)
MX (1) MX368178B (es)
PL (1) PL3083554T3 (es)
PT (1) PT3083554T (es)
RS (1) RS58594B1 (es)
SA (1) SA516371324B1 (es)
SI (1) SI3083554T1 (es)
TR (1) TR201904327T4 (es)
WO (1) WO2015094912A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074773A (zh) 2014-09-09 2017-08-18 拜耳制药股份公司 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
US10745382B2 (en) * 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2017153235A1 (de) * 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
AU2018251758B2 (en) 2017-04-10 2021-11-18 Bayer Aktiengesellschaft Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
JP7065117B2 (ja) 2017-05-18 2022-05-11 イドーシア ファーマシューティカルズ リミテッド Ｎ－置換インドール誘導体
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
JP7488269B2 (ja) * 2019-01-22 2024-05-21 キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド Ｐｇｅ２／ｅｐ４シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
CN100352804C (zh) * 1999-03-17 2007-12-05 阿斯特拉曾尼卡有限公司 酰胺衍生物
WO2005021508A1 (en) * 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
SI1664016T1 (sl) 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
BRPI0510598A (pt) * 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP2035376B1 (en) * 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
SG173027A1 (en) * 2009-01-30 2011-08-29 Toyama Chemical Co Ltd N-acyl anthranilic acid derivative or salt thereof
DK2607348T3 (da) * 2009-03-31 2021-05-25 Renascience Inc Inhibitor af plasminogenaktivatorinhibitor-1
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
WO2012117097A1 (en) 2011-03-03 2012-09-07 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
BR112014004545A2 (pt) * 2011-08-31 2017-04-04 Amakem Nv inibidores leves de rock
MX347855B (es) * 2011-09-16 2017-05-16 Sanofi Sa Derivados de anilina, su preparación y su aplicación terapéutica.
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors

Also Published As

Publication number Publication date
MX2016007861A (es) 2017-01-11
PT3083554T (pt) 2019-06-11
AU2014366371B2 (en) 2017-02-16
CA2929562A1 (en) 2015-06-25
HUE043614T2 (hu) 2019-08-28
CY1121677T1 (el) 2020-07-31
PL3083554T3 (pl) 2019-08-30
TR201904327T4 (tr) 2019-04-22
DK3083554T3 (da) 2019-05-13
KR20160086905A (ko) 2016-07-20
JP6200596B2 (ja) 2017-09-20
EP3083554B1 (en) 2019-03-13
EA201690911A1 (ru) 2016-09-30
WO2015094912A1 (en) 2015-06-25
JP2017500309A (ja) 2017-01-05
CN105793236B (zh) 2017-10-10
AU2014366371A1 (en) 2016-05-19
KR101937186B1 (ko) 2019-01-10
US10005721B2 (en) 2018-06-26
SI3083554T1 (sl) 2019-04-30
EA028675B1 (ru) 2017-12-29
LT3083554T (lt) 2019-05-10
RS58594B1 (sr) 2019-05-31
SA516371324B1 (ar) 2018-03-22
CN105793236A (zh) 2016-07-20
US20160251306A1 (en) 2016-09-01
ES2727329T3 (es) 2019-10-15
HRP20190793T1 (hr) 2019-06-28
EP3083554A1 (en) 2016-10-26
ME03398B (me) 2020-01-20

Similar Documents

Publication Publication Date Title
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
JO3318B1 (ar) مثبطات bace
MY176803A (en) Polymorph of syk inhibitors
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
UA114325C2 (uk) Феноксіетилпіперидинові сполуки
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2016007985A (es) Compuestos de fluorofenilpirazol.
EA201690593A1 (ru) Новые соединения мочевины

Legal Events

Date Code Title Description
FG Grant or registration